Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07843472

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

Conditions: Obesity or Overweight, Cardiovascular Disease

Sex: All

Ages: 40 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 2500

Sponsor: Hoffmann-La Roche

Location: Pinnacle Research Group Anniston Alabama

Summary

This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).

Eligibility Criteria

Inclusion Criteria: * Participants with BMI ≥ 27 kg/m² and established CVD * History of at least one self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * Known history of Type 1 diabetes mellitus * Current or previous treatment with petrelintide or any other amylin analog

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07843472). StuddyBuddy aggregates publicly available trial information.